Picard Medical, Inc. is a healthcare equipment company specializing in the development, manufacturing, and commercialization of advanced medical device solutions, with a primary focus on cardiac care. Its core product is the implantable SynCardia Total Artificial Heart, which is designed to temporarily replace the full function of a human heart in patients suffering from end-stage heart failure. This total artificial heart is the only system of its kind approved by both the U.S. Food and Drug Administration and Health Canada, and it is recognized globally as the most widely used and clinically studied artificial heart technology. Over 2,100 SynCardia systems have been implanted across 27 countries, serving as a critical bridge to heart transplantation for those with severe biventricular failure. As the parent company of SynCardia Systems, LLC, Picard Medical, Inc. plays a vital role in advancing life-saving cardiac technologies and addressing the needs of patients with advanced heart disease. Its innovative products underpin its significance within the medical devices sector, contributing to major advancements in artificial organ technology and modern cardiovascular treatment.